WUXI BIO: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2025

Wuxi Bio announced its financial results for the six months ending June 30, 2025. During this period, revenue increased by 16.1% year-on-year to RMB 9.953 billion, with a gross margin improvement of 3.6 percentage points to 42.7%. Net profit surged by 54.8% year-on-year to RMB 2.757 billion, with the net profit margin rising from 20.8% to 27.7%. The profit attributable to owners of the company grew by 56.0% to RMB 2.339 billion.During the period, the company added 86 integrated projects, bringing the total to 864, which includes 429 preclinical projects, 344 early clinical projects, 67 late-stage clinical projects, and 24 commercial production projects. The total value of unfulfilled orders increased to USD 20.3 billion, comprising unfulfilled service orders of USD 11.4 billion and unfulfilled potential milestone payment orders of USD 9.0 billion. The total value...Show More

Wuxi Bio announced its financial results for the six months ending June 30, 2025. During this period, revenue increased by 16.1% year-on-year to RMB 9.953 billion, with a gross margin improvement of 3.6 percentage points to 42.7%. Net profit surged by 54.8% year-on-year to RMB 2.757 billion, with the net profit margin rising from 20.8% to 27.7%. The profit attributable to owners of the company grew by 56.0% to RMB 2.339 billion.During the period, the company added 86 integrated projects, bringing the total to 864, which includes 429 preclinical projects, 344 early clinical projects, 67 late-stage clinical projects, and 24 commercial production projects. The total value of unfulfilled orders increased to USD 20.3 billion, comprising unfulfilled service orders of USD 11.4 billion and unfulfilled potential milestone payment orders of USD 9.0 billion. The total value of unfulfilled orders over the past three years rose to USD 4.2 billion.The company continues to advance its global capacity layout, with the MFG6 Phase II capacity at its Ireland facility upgraded to 6,000 liters, and the first engineering batch production and PPQ production batches completed. Construction has commenced on a new modular biopharmaceutical production facility in Singapore. The new microbial commercial production base project in Chengdu has officially started, equipped with 15,000-liter fermentation tanks. The company will continue to focus on enhancing its integrated platform, strengthening capacity, and driving operational excellence through WBS lean implementation and digital measures.